The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Valeant Pharmaceuticals International Inc

NYSE: VRX
Last

(U.S.) $36.95

Today's change+4.30 +13.16%
Updated May 3 2:21 PM EDT. Delayed by at least 15 minutes.
 

Valeant Pharmaceuticals International Inc

NYSE: VRX
Last

(U.S.) $36.95

Today's change+4.30 +13.16%
Updated May 3 2:21 PM EDT. Delayed by at least 15 minutes.

Valeant Pharmaceuticals International Inc Hits New 20-day High

Valeant Pharmaceuticals International Inc is up sharply today, rallying (U.S.)$4.30 or 13.16% to (U.S.)$36.95 and setting a new 20-day high. Over the last five days, shares have gained 1.98%, but are down 63.65% for the last year to date. Shares have underperformed the S&P 500 by 81.28% during the last year.

Key company metrics

  • Open(U.S.) $33.11
  • Previous close(U.S.) $32.65
  • High(U.S.) $38.50
  • Low(U.S.) $32.25
  • Bid / Ask(U.S.) $36.94 / (U.S.) $36.95
  • YTD % change-63.65%
  • Volume48,740,396
  • Average volume (10-day)23,952,009
  • Average volume (1-month)34,667,602
  • Average volume (3-month)20,607,197
  • 52-week range(U.S.) $25.27 to (U.S.) $263.81
  • Beta0.21
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forward3.76×
  • Forward PEG0.31×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.77
Updated May 3 2:21 PM EDT. Delayed by at least 15 minutes.
S&P TSX1.30%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Revenue2,7892,7872,7322,191
Total other revenue--------
Total revenue2,7892,7872,7322,191
Gross profit2,0522,1392,0471,616
Total cost of revenue737648685575
Total operating expense2,5672,3392,3911,668
Selling / general / administrative726698686574
Research & development961028156
Depreciation / amortization775679585365
Interest expense (income), net operating--------
Unusual expense (income)19118217792
Other operating expenses, total43301776
Operating income222448342523
Interest income (expense), net non-operating-432-420-413-298
Gain (loss) on sale of assets--------
Other--------
Income before tax-213-6-65155
Income after tax-33752-5275
Income tax, total124-57-1381
Net income-33650-5374
Total adjustments to net income--------
Net income before extra. items-33650-5374
Minority interest1-2-1-1
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-33650-5374
Inc. avail. to common incl. extra. items-33650-5374
Diluted net income-33650-5374
Dilution adjustment0000
Diluted weighted average shares345351344343
Diluted EPS excluding extraordinary itemsvalue per share-0.980.14-0.150.21
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share-0.470.570.190.34